Media Coverage

Shares of LabCorp moved lower following the afternoon disclosure and are trading down $1.51 to $164.12. LabCorp competitor Quest Diagnostics (DGX) gave up some of its gains as well but the shares remain up 51c to $98.67 in afternoon trading.

While the ultimate impact of UnitedHealthcare's newly launched Preferred Laboratory Network remains to be seen, some clinical lab players are suggesting it could be the first step in a broader trend.[CR-LF][CR-LF]Last week UHC announced the lab companies — AmeriPath/DermPath, a division of Quest Diagnostics; BioReference and its GeneDx business; Invitae; Laboratory Corporation of America; Mayo Clinical Laboratories; and Quest — it had selected as participants in its PLN program, which will go into effect on July 1, 2019.

Healthcare Technology Analyst Gill holds a conference call with CEO Rusckowski on May 2 at 1 pm hosted by JPMorgan.

Quest Diagnostics Incorporated executed a shelf takedown of $500 million aggregate principal amount of its 4.200% senior notes due 2029. Goldman Sachs, Mizuho Securities, Morgan Stanley, J.P. Morgan Securities and Wells Fargo Securities acted as joint book-running managers for the offering.[CR-LF][CR-LF]Quest Diagnostics Incorporated is the world’s leading provider of diagnostic information services.

The most recent version of an annual report issued by Quest Diagnostics indicates that 4.4 percent of workplace drug tests in 2018 were positive for illicit drugs, an increase over the 4.2 percent positivity rate in 2017 and the highest rate since 2004. According to Quest, the increase was largely fueled by marijuana use. Across the U.S. work force, the percentage of drug tests that were positive for marijuana rose from 2.6 percent in 2017 to 2.8 percent in 2018.

Genomic Vision (Paris:GV) (FR0011799907 - GV), a company specialized in the development of in-vitro diagnostic (IVD) tests for the early detection of cancers and genetic diseases and applications for life sciences research (LSR), today announced its revenue and cash position1 at March 31, 2019. First quarter 2019 revenue In € thousands Q1 2019 Q1 2018 Revenue from R&D collaboration with Quest Diagnostics 75 75 Sales of products and

With the recent formation of the Get the Medications Right (GTMRx) Institute, Quest Diagnostics and the other institute co-founders aim to drive the use of advanced diagnostics for guiding patient treatment.[CR-LF][CR-LF]Launched this month by organizations including J&J, Medecision, and the American College of Clinical Pharmacy, the institute will function "as an advocacy entity" for companion diagnostics and pharmacogenomic testing, said Steve Goldberg, vice president, medical affairs, population health and chief health officer, health and wellness at Quest, and a member of the GTMRx board.

Changes in state laws regarding the treatment of marijuana, which are in direct conflict with federal law, have raised concerns and caused confusion among employers and employees regarding standards for drug-free workplaces and employment drug testing procedures and programs. An Arizona US District Judge is the latest to weigh in on the matter—ruling on the side of a Walmart worker who had been fired after failing a company drug test.[CR-LF][CR-LF]US employers are feeling the impact of liberalized marijuana laws, according to employment drug testing performed by Quest Diagnostics, a leading provider of diagnostic information services.

One day after the Texas House overwhelmingly voted to virtually decriminalize the possession of small amounts of marijuana for first-time offenders, the president of the Texas Senate effectively drove a stake through the heart of the measure.[CR-LF][CR-LF]"I join with those House Republicans who oppose this step toward legalization of marijuana," Lt. Gov. Dan Patrick said in a tweet Tuesday morning. Marijuana use is on the rise among US workers, a study from Quest Diagnostics found, increasing by 16% since 2014.

An alliance of independent health systems across Massachusetts has expanded from three to 10 organizations, enabling them to leverage cheaper contracts while maintaining their autonomy.[CR-LF][CR-LF]The Massachusetts Value Alliance, which initially formed in 2016, is a collaboration of 14 hospitals in the state that work together on group purchasing contracts and share best practices in order to be competitive in their market while still remaining independent. The combined health systems serve about 2 million people. Since the Massachusetts alliance formed three years ago, the organizations have worked together to negotiate on lab referral contracts. The members waited until their contracts were up and decided to go forward with one contract with Quest Diagnostics.